妥拉洛尔 T68164

Product Introduction
Bioactivity


英文名: Tolamolol

描述: Tolamolol 是一种选择性 β肾上腺素能阻滞剂，能显著降低运动诱导的S-T段抑制程度，可用于治疗心律失常。

体内活性: Forty-two patients with angina pectoris have completed a randomized, double-blind trial comparing Tolamolol 100 mg and 200 mg with propranolol 80 mg, practolol 100 mg, and placebo, all given three times a day. Tolamolol 200 mg thrice daily was found to be equivalent to propranolol 80 mg thrice daily in anti-anginal efficacy. Anginal attack rates and trinitrin consumption were significantly reduced by all active treatments as compared with the placebo but Tolamolol and propranolol were the most effective. Tolamolol 200 mg thrice daily was most effective in reducing blood pressure, while propranolol was most effective in reducing the resting heart rate. All treatments except the placebo significantly increased the amount of exercise that could be performed before angina appeared (exercise work), while the Tolamolol 200 mg thrice daily significantly reduced Robinson's index when compared with all other active agents.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 18.33 mg/mL (53.23 mM)


相关产品: Tizanidine hydrochloride | (±)-Levomepromazine-d6 | Nortriptyline hydrochloride | Neldazosin | Octopamine hydrochloride | Arformoterol Tartrate | (3aR,9aR)-Fluparoxan | Niaprazine | Salbutamol hemisulfate | Maprotiline hydrochloride

相关库: Anti-Cancer Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Inhibitor Library | GPCR Compound Library | Bioactive Compound Library

妥拉洛尔 T68164信息由TargetMol中国为您提供，如您想了解更多关于妥拉洛尔 T68164报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途